Three-way sensitivity analysis assuming similar grade distribution between finasteride and placebo arms
| Relative risk reduction (%) . | Cost of finasteride (U.S. $/mo) . | Lifetime prevalence (men diagnosed after age of 50 yr) . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | 151.0% ($) . | 30.0% ($) . | 40.0% ($) . | 50.0% ($) . | |||
| 25 | 15 | 114,516 | 65,071 | 48,749 | 35,941 | |||
| 30 | 261,267 | 143,820 | 104,844 | 73,924 | ||||
| 62 | 578,411 | 314,006 | 226,072 | 156,010 | ||||
| 50 | 15 | 51,433 | 26,806 | 18,733 | 12,481 | |||
| 30 | 124,344 | 65,709 | 46,307 | 30,999 | ||||
| 62 | 281,911 | 149,783 | 105,897 | 71,019 | ||||
| 80 | 15 | 27,696 | 12,304 | 7,260 | 3,357 | |||
| 30 | 72,908 | 36,253 | 24,120 | 14,544 | ||||
| 62 | 170,617 | 88,008 | 60,555 | 38,721 | ||||
| Relative risk reduction (%) . | Cost of finasteride (U.S. $/mo) . | Lifetime prevalence (men diagnosed after age of 50 yr) . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | 151.0% ($) . | 30.0% ($) . | 40.0% ($) . | 50.0% ($) . | |||
| 25 | 15 | 114,516 | 65,071 | 48,749 | 35,941 | |||
| 30 | 261,267 | 143,820 | 104,844 | 73,924 | ||||
| 62 | 578,411 | 314,006 | 226,072 | 156,010 | ||||
| 50 | 15 | 51,433 | 26,806 | 18,733 | 12,481 | |||
| 30 | 124,344 | 65,709 | 46,307 | 30,999 | ||||
| 62 | 281,911 | 149,783 | 105,897 | 71,019 | ||||
| 80 | 15 | 27,696 | 12,304 | 7,260 | 3,357 | |||
| 30 | 72,908 | 36,253 | 24,120 | 14,544 | ||||
| 62 | 170,617 | 88,008 | 60,555 | 38,721 | ||||
NOTE: Results are cost per life year saved.